147 results about "Transplant rejection" patented technology

KLRB1 binding agents (in particular anti-KLRB1 antibodies and antigen binding portion thereof) and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, INKT, peTh2, ILC2, ILC3, NK cells, and / or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.

The invention discloses a monoclonal antibody targeting all CD45 subtypes and application of the monoclonal antibody, and belongs to the field of monoclonal antibody preparation. The hybridoma cell strain capable of stably secreting all anti-human CD45 subtype antibodies is successfully obtained by stably expressing short and long molecular subtypes of human CD45 extracellular regions in L929 mouse fibroblasts, immunizing BALB / c mice with L929 cells expressing the two molecular subtypes of human CD45, and fusing splenocytes with SP20 myeloma cells after the serum titer reaches the standard. And the monoclonal antibody targeting all subtypes of CD45 is obtained. The monoclonal antibody provided by the invention shows a high-affinity binding characteristic with all human CD45 molecular subtypes, has important application value in the aspect of human CD45 molecular detection, and can be used as a therapeutic antibody in the fields of tumor immunotherapy, autoimmune disease treatment, transplant rejection resistance and the like.

KLRB1 binding agents (in particular anti-KLRB1-antibodies and antigen binding portion thereof) with increased humanness and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells, (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, iNKT, peTh2, ILC2, ILC3, NK cells, and / or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.

The present invention proposes an activatable biomimetic probe with aggregation-induced emission and its application. The biomimetic probe is obtained by incubating and combining the H2O2-responsive aggregation-induced emission (AIE) molecule MTBPB with dextran particles (GPs). The biomimetic probe can specifically target macrophages. Infiltrating macrophages produce a large amount of H2O2 under the stimulation of inflammatory cytokines, thereby activating the fluorescence signal generated by the biomimetic probe, which can be used for early diagnosis of transplant rejection reactions and improve accuracy.

The present invention concerns the use of a molecule chosen from a globin, a globin protomer or an extracellular hemoglobin of Annelids, for treating and / or preventing at least one complement-activation associated disease, preferably ischemia / reperfusion injury and / or transplant rejection.

Disclosed are novel methods of assessing transplant rejection status in a transplant recipient, such as a kidney transplant recipient. The diagnostic method identifies stable subjects, subjects undergoing cell mediated rejection processes, and subjects undergoing antibody mediated rejection processes using measurement of TCR subunit repertoire diversity. The proportion of unique TCR alpha and beta subunit sequences to total unique TCR subunit sequences (total sequences for alpha, beta, delta, and gamma subunits) provides a diagnostic measure that can identify stable subjects, subjects undergoing cell mediated rejection processes, and subjects undergoing antibody mediated rejection processes. Methods of treatment include administration of a suitable treatment if antibody mediated rejection or cell mediated rejection is detected.

Provided herein, inter alia, are novel compositions and solid forms of Compound 1 useful for the prevention and / or treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage renewal, congenital cartilage malformations, and / or intermediates associated with IFN [alpha], interferon ("interferon disease", etc. In particular type I or type III interferon disease), diseases associated with excessive secretion of IL-12 and / or IL-23. # imgabs0 #

The present disclosure relates to anti-human CD154 antibodies having a modified effector function. The present disclosure also relates to the use of these anti-human CD154 antibodies in the treatment of conditions associated with CD154 activation, the conditions associated with CD154 activation are, for example, transplant rejection, inflammatory conditions and diseases, dysfunctional immune responses associated with viral infections and diseases, autoimmune conditions and diseases, allergic conditions, atherosclerotic conditions, or neurodegenerative conditions and diseases. The present disclosure also relates to the use of these anti-human CD154 antibodies in inducing central tolerance and hematopoietic cell chimerism in transplanted patients.

Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.

The disclosure describes T cells that express chimeric antigen receptors (CARs), as well as pharmaceutical compositions comprising T cells and methods of making and using such T cells. Particularly, this disclosure describes T cells expressing a CAR that specifically bind to pathologic T-cells, and methods of use in the treatment of autoimmune disease, transplant rejection, T cell malignancies, and chronic inflammatory disease.

The invention belongs to the technical field of biomedicine, and particularly relates to a diagnostic marker for lung transplantation rejection and application of the diagnostic marker. The invention discloses one or more of OIT3, CAMP, USP4, IPO9 and PON1 as markers for diagnosis, monitoring, curative effect evaluation or prognosis evaluation of the lung transplantation rejection for the first time, and diagnosis, monitoring, curative effect evaluation or prognosis evaluation of the lung transplantation rejection can be realized by detecting the content, expression quantity and / or activity of the markers. The invention discloses that the OIT3 can be used as a diagnosis and treatment target of the lung transplantation rejection for the first time, and diagnosis, monitoring, curative effect evaluation or prognosis evaluation of the lung transplantation rejection can be realized by detecting the content, expression quantity and / or activity of the OIT3; the lung transplantation rejection reaction can be prevented and / or treated through the OIT inhibitor.

The present invention relates to a gelatin-coated acellular dermal tissue and a use thereof. More specifically, the present invention relates to: an acellular dermal tissue in which gelatin derived from human skin tissue is crosslinked on the surface of the acellular dermal tissue; and a use thereof for treating skin damage. The gelatin-coated acellular dermal tissue according to the present invention has predetermined physical properties so as to provide ease of handling, and also eliminates toxicity and transplant rejection responses, and thus can be effectively used for treating patients with skin tissue damage.

Described herein are kits, compositions, and methods for detecting porcine antigens in biological samples. The kit comprises a support, anti-porcine antibodies coupled to the support, and instructions for preparing lysates from a porcine donor source and contacting the lysates with the anti-porcine antibodies. The kit may be for use in determining the risk of transplant rejection in a human subject receiving or being considered for receiving a transplant from the porcine donor.

To provide Akt3 modulators and compounds and pharmaceutical compositions for treating diseases by modulation of Akt3 signaling.SOLUTION: A compound of Formula Ib or Ic, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound for treating a disease in a subject in need thereof, A pharmaceutical composition wherein the treatment comprises administering to a subject an effective amount of the compound; optionally wherein the disease is selected from the group consisting of neurodegenerative diseases, cachexia, eating disorders, obesity, complications of obesity, inflammatory diseases, virally-induced inflammatory reactions, Gulf War Syndrome, tuberous sclerosis, retinitis pigmentosa, graft rejection, cancer, autoimmune diseases, ischemic tissue injury, traumatic tissue injury and combinations thereof.SELECTED DRAWING: Figure 6

This invention relates to double-stranded oligonucleotides complementary to JAK1 that result in the regulation of JAK1 expression. Regulation of JAK1 expression is beneficial for a range of medical disorders, including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. The invention also includes compositions comprising double-stranded oligonucleotides and therapeutic methods using double-stranded oligonucleotides.

Provided is a modified regulatory T cell capable of recognizing cells of the liver, capable of treating and / or preventing transplant rejection or immune-mediated damage, and capable of promoting regeneration of cells of the liver.SOLUTION: The present invention provides engineered regulatory T cells (Tregs) comprising a chimeric antigen receptor (CAR), wherein said CAR comprises an antigen recognition domain that specifically binds to the asialoglycoprotein receptor (ASGR). The invention also provides a method of promoting liver tissue repair and / or regeneration in a subject, said method comprising administering to said subject a modified Treg comprising a CAR, or a pharmaceutical composition comprising said modified Treg, wherein said CAR comprises a liver-specific antigen recognition domain.SELECTED DRAWING: None

Processes and materials to detect cancer, transplant rejection, or fetal genetic abnormalities from a biopsy are described. In some cases, cell-free nucleic acids can be sequenced, and the sequencing result can be utilized to detect sequences indicative of a neoplasm, transplant rejection, or fetal genetic abnormality. Detection of somatic variants occurring in phase and / or insertions and deletions (indels) can indicate the presence of cancer, transplant rejection, or fetal genetic abnormalities in a diagnostic scan, and a clinical intervention can be performed.

This disclosure relates to anti-human CD154 antibodies with modified effector function. This disclosure also relates to the use of these anti-human CD154 antibodies in treating conditions associated with CD154 activation, such as transplant rejection, inflammatory conditions and disease, dysfunctional immune responses associated with viral infections and diseases, autoimmune conditions and disease, allergic conditions, atherosclerotic conditions, or neurodegenerative conditions and diseases. It also relates to the use of these anti-human CD154 antibodies in inducing central tolerance and hematopoietic chimerism in transplant patients.

The invention relates to the technical field of medicines, and discloses camphorsulfonate, a crystal form, a composition and a preparation method and application thereof, and the camphorsulfonate is AXL kinase inhibition camphorsulfonate. The crystal form of the camphorsulfonate is substantially pure. The basically pure AXL kinase inhibition camphorsulfonate crystal form disclosed by the invention has good performance and high bioavailability; therefore, the compound can be used for preparing medicines for treating and / or preventing proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancers, virus infectious diseases, heart failure, cardiovascular diseases or other diseases of mammals.

The application relates to the diagnosis and treatment of diseases, including cancer, chronic infectious diseases, autoimmune diseases, inflammatory disorders, as well as the prevention of transplant rejection. The invention provides, and involves the use of, antibody molecules that bind CD28 in a non super-agonistic manner and which also bind to CTLA-4. The antibody molecules may form part of a bispecific molecule which binds e.g. a tumor associated antigen or a further T cell antigen, such as CD3.

The disclosure relates to compositions and methods useful for gene therapy and for the prevention and treatment of cardiac allograft rejection in the transplant setting.

This invention relates to the use of IL-6 inhibitors for preventing or inhibiting lung transplantation rejection in a subject. In particular, this invention relates to methods of treatment of antibody mediated rejection (AMR) of a lung transplant in a subject in need thereof comprising a combination therapy of (i) administration to the subject of an antibody or fragment which is capable of inhibiting human IL-6; and (ii) administration to the subject of an immunosuppressive therapy, wherein the immunosuppressive therapy does not comprise any antibody or fragment thereof which is capable of inhibiting human IL-6.

The invention relates to the technical field of medicines, and discloses a salt, a crystal form and a composition of an AXL kinase inhibitor as well as a preparation method and application of the salt, the crystal form and the composition of the AXL kinase inhibitor, and the salt is hydrochloride, sulfate, phosphate, mesylate, benzene sulfonate, p-toluenesulfonate, camphorsulfonate, maleate and oxalate. The crystalline form of the AXL kinase inhibitor salt is substantially pure. The basically pure AXL kinase inhibitor crystal form disclosed by the invention has good performance and high bioavailability; therefore, the compound can be used for preparing medicines for treating and / or preventing proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancers, virus infectious diseases, heart failure, cardiovascular diseases or other diseases of mammals.

The present invention discloses salts of a Compound 1:useful in the prophylaxis and / or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and / or disruption of cartilage homeostasis, congenital cartilage malformations, and / or diseases associated with hypersecretion of IL6 or interferons.

The present invention is related to human platelet lysate or a fraction that is enriched for human platelet lysate derived extracellular vesicles and their use in medicine, particularly for the prevention and / or treatment of inflammatory driven diseases, neurodegenerative diseases, immune / autoimmune diseases, cardiovascular diseases, dermatologic diseases, orthopedic diseases, tissue regenerative medicine, oncologic diseases, infectious diseases, transplant rejections, stroke, ischemia or Graft-versus-Host Disease. The present invention is further related to a method of manufacture of a pharmaceutical preparation or a diagnostic preparation or a cosmetic preparation comprising the step of adding human platelet lysate or a fraction that is enriched for human platelet lysate derived extracellular vesicles to the pharmaceutical preparation or a diagnostic preparation or a cosmetic preparation.

To provide compositions comprising components of multi-component CALs or CARs, and to provide methods for treating autoimmune diseases and the like.SOLUTION: A composition is provided comprising a TCR recognition domain and one or both of (a) an intracellular signaling domain and (b) a first-type protein interaction domain. Further provided is a method for treating or preventing autoimmune disease, transplant rejection, or graft-versus-host disease.SELECTED DRAWING: Figure 10

The invention discloses compounds of Formula (I), wherein the compounds are used as anti-inflammatory agents, for treatment or prevention of a number of diseases or conditions such as atherosclerosis, auto-immune diseases, psoriasis, multiple sclerosis, transplant rejection, asthma, bacterial infection, rhinovirus infection, brain ischemia, ischemia-reperfusion injury, limb ischemia, acute kidney injury, diabetic nephropathy, sepsis, acute respiratory distress syndrome (ARDS), cancer, osteoarthritis, sepsis-induced kidney injury, liver disease, and septic and cardiogenic shock.

The present application relates to an Intercellular Adhesion Molecule 2 (ICAM-2) binding polypeptide. This ICAM-2 binding polypeptide comprises a fibronectin type III (FN3) domain having at least one modified loop amino acid sequence and, optionally, a modified beta strand. The one or more modified loop sequences, together with the optional beta strand modifications, enable selective binding to ICAM-2. Also disclosed are conjugates that include the ICAM-2 binding polypeptide, polynucleotides encoding the same, and methods of using these materials for inhibiting transplant organ rejection as well as treatment of hypertension and cancer.

The invention relates to the technical field of medicines, and particularly discloses an engineered drug-loaded macrophage for resisting transplant rejection. PD-L1 is overexpressed on the surface of a cell membrane of the engineered drug-loaded macrophage, and the engineered drug-loaded macrophage internally contains nanoparticles encapsulated with rapamycin. Due to the biological characteristic that the macrophages can respond to inflammation signals, the engineered drug-loaded macrophages can be efficiently recruited to rejection reaction parts by chemotactic factors of transplantation parts, and the engineered drug-loaded macrophages can penetrate a tissue barrier as an active carrier, respond to external stimulation to exocytosis and release nanoparticles encapsulated with rapamycin after reaching a target position, and can be used for preparing a drug carrier. Local precise delivery of PD-L1 and rapamycin is realized, and immunosuppression toxicity of systemic administration is reduced.

Provided herein are microfluidic arrays and miR panels useful in the identification of human subjects experiencing or at risk of experiencing an acute heart allograft rejection. Further provided are methods of identifying human subjects experiencing or at risk of experiencing an acute heart allograft rejection, including Acute Cellular Rejection (ACR) or antibody-mediated rejection (AMR). Further provided are system, apparatus, device, method and / or computer program product aspects, and / or combinations and sub-combinations thereof, for detecting an allograft rejection.